A.P.L.
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
A.P.L. is an injectable biologic (BLA-approved) developed by Ferring Pharmaceuticals. The specific mechanism of action and indication are not publicly detailed in available data; however, the product has maintained market presence since 1974. As an established biologic in the 'OTHER_BIO' category, it represents a legacy therapeutic agent.
LOE Approaching
Product is in late lifecycle with moderate competitive pressure (30/100); team sizing and investment priorities likely shifting toward defense and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
A.P.L. currently shows zero linked job openings, reflecting its late-lifecycle stage and limited hiring momentum. Career roles on this product are primarily defensive—focused on maximizing remaining market share, maintaining relationships, and managing transition to biosimilars.
Brand Manager (Lifecycle Defense)Field Sales
Worked on A.P.L. at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.